bioMérieux S.A. (OTCMKTS:BMXMF – Get Free Report) saw a significant decrease in short interest during the month of August. As of August 31st, there was short interest totalling 225,800 shares, a decrease of 15.5% from the August 15th total of 267,100 shares. Based on an average trading volume of 100 shares, the days-to-cover ratio is presently 2,258.0 days.
Wall Street Analysts Forecast Growth
Separately, UBS Group raised bioMérieux to a “strong-buy” rating in a report on Thursday, August 22nd.
Check Out Our Latest Report on BMXMF
bioMérieux Stock Performance
About bioMérieux
bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.
Featured Articles
- Five stocks we like better than bioMérieux
- Earnings Per Share Calculator: How to Calculate EPS
- e.l.f. Beauty: The High-Growth Stock You Shouldn’t Ignore
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Boeing’s Setback Could Be Investors’ Big Opportunity: Here’s Why
- Low PE Growth Stocks: Unlocking Investment Opportunities
- What the Bulls and Bears Are Saying About NVIDIA Stock
Receive News & Ratings for bioMérieux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioMérieux and related companies with MarketBeat.com's FREE daily email newsletter.